Gan & Lee Pharmaceuticals (SHA:603087) said its GLR1075 injection completed the first subject dosing in phase one clinical trials in China.
GLR1075 is intended to treat hypoproteinemia, or low blood protein, in cirrhotic ascites, according to a Shanghai bourse filing on Tuesday.
Shares of the pharmaceutical company slipped 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments